Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017 (2017), Article ID 2412486, 7 pages
Research Article

LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease

1Research Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, Morocco
2Department of Neurology and Neurogenetics, Specialties Hospital, Rabat, Morocco
3Laboratory of Public Health, Medical School and Pharmacy, Mohammed V University, Rabat, Morocco

Correspondence should be addressed to Ahmed Bouhouche

Received 9 December 2016; Accepted 23 March 2017; Published 30 March 2017

Academic Editor: Daniel Berwick

Copyright © 2017 Ahmed Bouhouche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The LRRK2 G2019S mutation is the most common genetic determinant of Parkinson’s disease (PD) identified to date. This mutation, reported in both familial and sporadic PD, occurs at elevated frequencies in Maghreb population. In the present study, we examined the prevalence of the G2019S mutation in the Moroccan population and we compared the motor and nonmotor phenotype of G2019S carriers to patients with idiopathic Parkinson’s disease. Methods. 100 PD patients were assessed for motor and nonmotor symptoms, current medication, and motor complication including motor fluctuations and dyskinesia. The LRRK2 G2019S mutation was investigated by direct sequencing in patients and ethnically matched controls, all of Moroccan origin. Results. Among the 100 PD Moroccan patients, 41 (41%) were carriers of the G2019S mutation. The mutation frequency was higher among probands with autosomal dominant inheritance (76%) than among sporadic ones (28%). Interestingly, G2019S mutation was also found in 5% of control individuals. Clinically, patients carrying the G2019S mutation have more dystonia (OR = 4.6, p = 0.042) and more sleep disorders (OR = 2.4, p = 0.045) than noncarriers. Conclusions. The LRRK2 G2019S prevalence in Morocco is the highest in the world reported to date. Some clinical features in G2019S carriers such as dystonia and sleep disturbances are worth noting.